LYMPHOMAS

Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.

Updated data shows chimeric antigen receptor (CAR)-modified T-cell therapies continue to remain effective for patients with non-Hodgkin lymphoma (NHL), according to findings presented at the 2015 ASH Annual Meeting.

Ibrutinib reduced risk of death by 84% against chlorambucil in treatment-naive elderly patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma.

Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease

Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

When John P. Leonard, MD, spoke at the American Society of Hematology inaugural meeting on Hematologic Malignancies about mantle cell lymphoma (MCL), he balanced his enthusiasm about the emerging benefits that tumor profiling brings to this disease with an acknowledgement that many important questions about mantle cell lymphoma remain unanswered.

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

The therapeutic palette for Hodgkin Lymphoma is growing, along with improvements in survival and cure rates.

The antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) was recently approved by the FDA as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients who have Hodgkin lymphoma and are at risk of relapse or progression.

The development of novel targeted drugs, such as brentuximab vedotin (Adcentris), against discrete cell surface proteins, such as CD30, has awakened a new way of thinking about targeted cancer biology

Guess the Diagnosis